Related Experiment Videos
Phase II trial of mitogauzone in malignant primary brain tumors
Cancer Treatment Reports
|March 1, 1985
Abstract:
Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitoguazone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.
Insights
Mitoguazone showed limited efficacy in treating recurrent malignant brain tumors. No tumor regressions were observed in 15 evaluable patients, with only four experiencing disease stabilization.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Primary malignant brain tumors often recur or progress despite initial treatments.
- Recurrent or progressive tumors present significant therapeutic challenges.
Purpose of the Study:
- To evaluate the efficacy of mitoguazone in patients with recurrent or progressive primary malignant brain tumors.
- To assess tumor response and disease stabilization following mitoguazone treatment.
Main Methods:
- A cohort of sixteen patients with recurrent/progressive primary malignant brain tumors was enrolled.
- Patients received mitoguazone at a starting dose of 500 mg/m2 intravenously on a weekly schedule.
- Tumor response was assessed in 15 evaluable patients.
Main Results:
- No objective tumor regressions were observed in the 15 evaluable patients.
- Four out of sixteen patients (25%) achieved stabilization of their disease.
- Mitoguazone demonstrated minimal anti-tumor activity in this patient population.
Conclusions:
- Mitoguazone appears to have limited efficacy as a treatment for recurrent or progressive primary malignant brain tumors.
- Further investigation into alternative therapeutic strategies for these challenging tumors is warranted.